Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Silletta

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Histology and Histopathology|January 27, 2006
Cell cycle alterations and lung cancerB Vincenzi, G Schiavon, M Silletta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2006
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patientsB Vincenzi, D Santini, A Russo, et al.
Breast Cancer Research and Treatment|February 23, 2026
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysisL Sisca, M G Polito, M Silletta, et al.
ESMO Open|June 18, 2021
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinomaI G Rapposelli, S Shimose, T Kumada, et al.
ESMO Open|November 30, 2021
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinibM Rimini, M Kudo, T Tada, et al.
ESMO Open|October 8, 2022
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysisM Rimini, L Rimassa, K Ueshima, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Histology and Histopathology|January 27, 2006
Cell cycle alterations and lung cancerB Vincenzi, G Schiavon, M Silletta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2006
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patientsB Vincenzi, D Santini, A Russo, et al.
Breast Cancer Research and Treatment|February 23, 2026
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysisL Sisca, M G Polito, M Silletta, et al.
ESMO Open|June 18, 2021
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinomaI G Rapposelli, S Shimose, T Kumada, et al.
ESMO Open|November 30, 2021
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinibM Rimini, M Kudo, T Tada, et al.
ESMO Open|October 8, 2022
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysisM Rimini, L Rimassa, K Ueshima, et al.
Pageof 1